30-second answerSell
Price versus value
- Price
- $137.72
- Fair value
- $82.88
- Potential value
- $114.81
- As of
- 2026-09-04
Main upside reason
FY2027 adjusted EPS could reach $12.88.
Main risk
FY2026 annual revenue growth falls below 8%.
Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
FY2027 adjusted EPS could reach $12.88.
FY2026 annual revenue growth falls below 8%.
Sell. The $137.72 report-date price is above $82.88 Fair value and $114.81 Potential value. A weak FY2026 revenue recovery is the main risk. Stronger adjusted earnings and fewer shares offer the clearest upside.4
The market quote was $137.72 on 2026-09-04 and available on 2026-09-08. House Fair value is $82.88, with Potential value of $114.81 on the 2026-09-08 analysis date.4
The view worsens if FY2026 revenue growth falls below 8%. That would weaken operating leverage, adjusted earnings, and the case for improved profitability.
The constructive case requires FY2027 adjusted EPS near the $12.88 estimate. Continued share reduction is a separate condition, not a result established by the dated share observations. Fewer diluted shares would spread profit across a smaller base and raise earnings per share for the same aggregate profit.145
The favorable cycle is demand-led. FY2027 revenue is expected to reach $99.52 billion, supporting continued adjusted-earnings recovery if pricing and costs remain controlled.1
Sell because the report-date price exceeds both Fair value and Potential value.4
The favorable cycle is demand-led. FY2027 revenue is expected to reach $99.52 billion, supporting continued adjusted-earnings recovery if pricing and costs remain controlled.1
Sell because the report-date price exceeds both Fair value and Potential value.4
The central downside is an early revenue slowdown followed by weak margin conversion. Slower buybacks would then leave more shares dividing the same profit, while higher required returns would further reduce value.
Citigroup has financial scale and broad geographic reach, but the evidence does not establish switching costs, network effects, proprietary integration, or another structural barrier. The recovery therefore does not support a durable moat claim.
Competition remains a conditional threat. Bank-like peers show stronger profitability, while payment and brokerage comparables have different economics. The mixed set is useful for comparison, but not as proof of direct customer losses.
The available evidence supports recovering earnings, not durable excess returns. Profitability must improve before investors can justify paying more for each dollar of future earnings.
None of the valuation methods used to calculate Fair value relies on a separate assumption about how long the competitive advantage lasts.
The highlighted cell is Fair value when every assumption sits at its base level ($82.88). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $14.2B after modeled capex of $4.8B, with terminal value at 37.3% of . A sudden drop in free cash flow is not projected unless capital spending relative to , reinvestment, or resets materially.
A beat strengthens the short recovery but does not establish durable post-FY2027 growth.
Meeting estimates confirms recovery, but the report-date price remains above Fair value.
A miss would weaken revenue, margin, and per-share earnings together.
The industry capex-to-revenue benchmark was 1.8% as of 2026-09-01, retrieved that day. This does not establish a bank capacity cycle.
The favorable cycle is demand-led. FY2027 revenue is expected to reach $99.52 billion, supporting continued adjusted-earnings recovery if pricing and costs remain controlled.
The adverse cycle begins if FY2026 revenue growth drops below 8%. Weak sales conversion would reduce profit growth before the longer-range assumptions can take effect.
No new allocation. The report-date price exceeds Potential value, while the earnings recovery is supported only through FY2027.4
Keep exposure defensive until price and operating evidence align. Do not treat a strong quarter as proof of durable recovery beyond FY2027.
The $137.72 report-date price exceeds $82.88 Fair value and $114.81 Potential value.4
Reduce or exit because the valuation already assumes more durable profitability than the evidence supports.
Dividend capacity does not offset the valuation gap, and the dividend-based value is heavily dependent on distant assumptions.
Sell because the report-date price stands above both Fair value and Potential value.4
The near-term recovery is credible, but evidence after FY2027 is too limited to support the valuation already reflected in the shares.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
This path becomes more plausible when revenue fails first and weak margin conversion follows. The result would be lower earnings per share and less willingness to pay for future profit.
FY2026 revenue growth below 8% would show that the expected rebound was weaker or more cyclical than assumed.
Provider-adjusted net margin below 18% for two post-FY2027 years would indicate that costs or business mix are absorbing the revenue recovery.
An assessed terminal P/E below 10.4x would mean profitability never earned the assumed valuation improvement.
A cost of equity above 11.1964% would reduce the present value of earnings, residual income, and dividends.2
FY2027 diluted shares above 1.8 billion would remove expected buyback support and reduce earnings per share.
The five developments that would weaken our investment case.
A breach would show that the rebound lacks expected breadth. Lower revenue would also reduce the operating leverage needed for adjusted earnings to recover faster than sales.
Current:FY2026 estimate: 12.41% year over year, dated 2026-09-08.
Alert ifBelow 8% for FY2026
Persistent weakness would indicate that costs or business mix are consuming the revenue recovery. That would lower future earnings and the value created above the required shareholder return.
Current:Base forecast target: 20.0% over five years, dated 2026-09-08.
Alert ifBelow 18% for two fiscal years after FY2027
A lower multiple would show that investors still view profitability as structurally weaker. Each dollar of future earnings would then command a lower share price.
Current:Base assumption: 13.0x; subject forward P/E: 10.64x on 2026-09-08.
Alert ifBelow 10.4x within 24 months
A higher required return would reduce the present value of future earnings and dividends even if operating forecasts were unchanged.
Current:9.1964% on 2026-09-08, retrieved 2026-09-08T15:44:20+00:00.
Alert ifAbove 11.1964% within 12 months
A reversal would leave more shares dividing aggregate income. Earnings per share would grow more slowly, weakening one of the recovery's main supports.
Current:FY2025 weighted average: 1.8731 billion; end-period count on 2026-09-08: 1.677437 billion.
Alert ifAbove 1.8 billion in FY2027
| Threat | Severity | Timeline | Mitigation |
|---|
| Pricing or customer-share pressure could limit revenue growth and prevent margin recovery. | high | Two consecutive fiscal years | Require Citigroup's revenue growth to remain within five percentage points of the peer set without accompanying margin deterioration. |
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Use book value per share with normalized ROE, cost of equity, and terminal growth to derive a justified price-to-book value.
Discount the explicit dividend path and its Gordon-growth terminal value at cost of equity.
Limitation: Terminal value is 74% of this model's value, above the 60% level at which the methodology flags concentration; the value leans on the years beyond the explicit forecast.
Solve for the growth rate that makes the model value equal the report-date share price.
The base path accepts the estimate-backed recovery but does not extend it indefinitely. It would weaken if post-FY2027 profitability fails to normalize or regional concentration rises materially.
Upside persists only if post-FY2027 earnings growth proves durable and the observed regional revenue breadth translates into steadier profit. Rising diluted shares or renewed margin weakness would disconfirm this path.6
Judge progress through revenue, adjusted earnings, margin, and diluted shares. Bank cash movement is too influenced by balance-sheet funding to use as an industrial earnings-quality test.
Slower growth would weaken operating leverage and adjusted earnings.
Weak conversion would lower future earnings and residual value.
A lower denominator raises earnings per share for unchanged income.4
Weak profitability would keep the price paid for future earnings compressed.3
| $71.88B |
| $75.34B |
| $78.07B |
| $80.72B |
| $85.23B |
| +4.3% |
| Gross profit | $75.78B | $69.37B | $67.90B | $71.12B | $75.05B | -0.2% |
| Operating income | $27.47B | $18.81B | $12.91B | $17.05B | $19.83B | -7.8% |
| Net income | $21.95B | $14.85B | $9.23B | $12.68B | $14.31B | -10.2% |
| EPS (diluted) | $10.14 | $7.00 | $4.04 | $5.94 | $6.99 | -8.9% |
| EBITDA | $31.43B | $23.07B | $17.47B | $21.36B | $24.20B | -6.3% |
| R&D | — | — | — | — | $2.33B | — |
| SG&A | $25.25B | $26.75B | $29.32B | $28.63B | $29.73B | +4.2% |
For a bank, reported cash movement is shaped by loans, deposits, and funding. Industrial free-cash-flow measures therefore do not provide a reliable bridge to common-equity value.4
Capital allocation matters mainly through dividends and repurchases. The declining share count supports per-share earnings, but FY2027 diluted shares must remain below 1.8 billion for that support to persist.
The supplied return evidence supports a bank-specific assessment of book capital and shareholder returns, not a clean industrial return-on-invested-capital series.
No ROIC-versus-WACC conclusion is made. The 13.18% WACC is reserved for enterprise methods, while the bank equity analysis uses shareholder return requirements.
Adjusted diluted EPS is estimated at $12.88, while revenue is estimated at $99.52 billion, as of and retrieved on 2026-09-08.
The recovery is credible through FY2027, but later years require extrapolation.
Diluted-average shares fell from 1.9558 billion in FY2023 to 1.8731 billion in FY2025. Filing data was retrieved on 2026-09-08.
Continued reductions would support earnings per share, but the future pace is not secured.
| Revenue | $85,225,000,000 |
|---|---|
| Cost of revenue | $10,178,000,000 |
| Gross profit | $75,047,000,000 |
| Operating expenses | $55,219,000,000 |
| Operating income | $19,828,000,000 |
| Non-operating items and tax | -$5,522,000,000 |
| Net income | $14,306,000,000 |
| Total assets | $2,657,202,000,000 |
|---|---|
| Cash | $349,579,000,000 |
| Current assets | $738,120,000,000 |
| Total liabilities | $2,443,380,000,000 |
| Current liabilities | $1,530,287,000,000 |
| Shareholders’ equity | $213,822,000,000 |
| Net income | $14,845,000,000 |
|---|---|
| Operating inflow | $25,069,000,000 |
| Depreciation and amortization | $4,262,000,000 |
| Stock-based compensation | $1,839,000,000 |
| Other operating adjustments | $4,123,000,000 |
| Operating cash flow | $25,069,000,000 |
| Cash available | $424,865,000,000 |
| Beginning cash | $262,033,000,000 |
| Financing inflow | $137,763,000,000 |
| Investing outflow | $79,455,000,000 |
| Capex | $5,632,000,000 |
| Other investing activities | $73,823,000,000 |
| Exchange-rate effect | $3,385,000,000 |
| Ending cash | $342,025,000,000 |
| Investing cash flow | -$79,455,000,000 |
| Financing cash flow | $137,763,000,000 |
Source: SEC EDGAR · Filed 2026-02-20 · SEC EDGAR
| Revenue by geography | Revenue | Share | YoY |
|---|---|---|---|
| International | $40.3B | 49.9% | 1.9% |
| North America | $39.7B | 49.2% | 9.2% |
| Corporate And Other Geographical | $668M | 0.8% | -68.4% |
Point-in-time financial data used in the 2026-09-08 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $70.8B | $25.2B | $14.9B | $53.9B | $51.2B | $2.8B | $3.7B | $1.5B | $9.3B | $2.3B | — | -$54.1B | $28.3B | — | $160.5B | $468.1B | $206.2B | 30.3% | — | 6.1% | — |
| 2017-12-31 | $72.4B | $26.4B | -$6.8B | -$8.8B | -$12.1B | $3.4B | $3.7B | $1.6B | $14.5B | $3.8B | — | -$38.8B | $66.9B | $160.5B | $180.5B | $479.5B | $236.7B | 31.4% | — | 4.8% | — |
| 2018-12-31 | $72.9B | $27.2B | $18B | $37B | $33.2B | $3.8B | $3.8B | $1.4B | $14.4B | $5B | — | -$73.1B | $44.5B | $180.5B | $188.1B | $483.4B | $232B | 32.2% | — | 8.7% | — |
| 2019-12-31 | $75.1B | $27.8B | $19.4B | -$12.8B | -$18.2B | $5.3B | $3.9B | $6.8B | $17.6B | $5.4B | — | -$23.4B | $42.9B | $188.1B | $193.9B | $474.2B | $248.8B | 31.8% | — | 8.4% | — |
| 2020-12-31 | $75.5B | $17.6B | $11B | -$23.5B | -$26.9B | $3.4B | $3.9B | $15.8B | $2.9B | $5.4B | — | -$92.4B | $233.6B | $193.9B | $309.6B | $644.7B | $271.7B | 18.1% | — | 8.0% | — |
| 2021-12-31 | $71.9B | $31.4B | $22B | $47.1B | $43B | $4.1B | $4B | -$3.7B | $7.6B | $5.2B | — | -$110.7B | $17.3B | $309.6B | $262B | $541.3B | $254.4B | 38.2% | — | 3.7% | — |
| 2022-12-31 | $75.3B | $23.1B | $14.8B | $25.1B | $19.4B | $5.6B | $4.3B | $1.8B | $3.3B | $5B | $66.8B | -$79.5B | $137.8B | $262B | $342B | $580.8B | $271.6B | 25.0% | — | 11.1% | — |
| 2023-12-31 | $78.1B | $17.5B | $9.2B | -$73.4B | -$80B | $6.6B | $4.6B | $1.8B | $2B | $5.2B | -$8.8B | -$8.5B | $687M | $342B | $260.9B | $506B | $286.6B | 16.5% | — | 12.3% | — |
| 2024-12-31 | $80.7B | $21.4B | $12.7B | -$19.7B | -$26.2B | $6.5B | $4.3B | — | $2.5B | $5.2B | $17.2B | $86.3B | -$38.3B | $260.9B | $276.5B | $498B | $287.3B | 21.1% | — | 12.9% | — |
| 2025-12-31 | $85.2B | $24.2B | $14.3B | -$67.6B | -$74.2B | $6.5B | $4.4B | — | $13.3B | $5.4B | $22.1B | -$108.3B | $238B | $276.5B | $349.6B | $675.4B | $315.8B | 23.3% | — | 10.4% | — |
Citigroup Inc. (C) trades at 10.6x forward earnings against a peer median of 12.9x. The comparison uses 4 peers: Bank of America Corporation, Wells Fargo & Company, American Express Company and The Charles Schwab Corporation, as of 2026-09-07 to 2026-09-08.
| Note |
|---|
| Mature banking growth | neutral | The forecast fades quickly after FY2027 rather than treating the rebound as a lasting high-growth cycle. |
Citigroup can benefit from the near-term recovery, but the evidence supports only a short duration before mature growth resumes.
| A lower price must coincide with FY2026 revenue growth above 8%, post-FY2027 adjusted margin above 18%, and FY2027 diluted shares below 1.8 billion. |
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
| Wells Fargo & Company |
| 11.4x |
| 3.3x |
| 12.6% |
| 37.4% |
| AXP | American Express Company | 16.2x | 3.1x | 34.4% | 20.3% |
| SCHW | The Charles Schwab Corporation | 14.0x | 7.3x | 20.3% | 52.3% |
